Maria Secrier

Principal Investigator
Google Scholar

I'm an Associate Professor at the UCL Genetics Institute in the Department of Genetics, Evolution and Environment. My research focus is genomic instability and tumour-immune crosstalk during cancer progression.

I received my bachelor's degree from Jacobs University (Bremen, Germany) and my PhD from the European Molecular Biology Laboratory (EMBL, Heidelberg) and the University of Heidelberg (Germany). Following my PhD I worked on the genomics of oesophageal cancer as a Research Associate at the Cancer Research UK Cambridge Institute, and on the identification of new targets and immuno-oncology as a Senior Scientist at AstraZeneca.


Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data.

Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma.

Patient-specific cancer genes contribute to recurrently perturbed pathways and establish therapeutic vulnerabilities in esophageal adenocarcinoma.

Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction.

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.

The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic.

Identification of prognostic phenotypes of esophageal adenocarcinoma in 2 independent cohorts.

Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics.

Molecular landscape of esophageal cancer: implications for early detection and personalized therapy.

Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.

A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy.

Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.

Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1.

Whole-genome sequencing of nine esophageal adenocarcinoma cell lines.

Signatures of mutational processes and associated risk factors in esophageal squamous cell carcinoma: a geographically independent stratification strategy?

Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.